ClinicalTrials.gg
RecruitingNCT07947186Updated Nov 18, 2026

Early Feasibility Study of a Novel Male Contraceptive Device: Safety, Usability, and Acceptability Outcomes

An interventional study of Galactic Cap in Male Contraception, Contraceptive Device and Pregnancy Prevention, sponsored by Indiana University. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Indiana University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a Phase 1 feasibility study evaluating the safety, barrier efficacy, and user acceptability of a novel male contraceptive device, the Galactic Cap (GC), an adhesive, polyurethane-based barrier designed to cover the glans penis. Unlike traditional condoms, the device adheres directly to the penile surface to improve fit, reduce slippage, and enhance sensation through increased skin-to-skin contact and improved heat transfer. The study will enroll 40 monogamous heterosexual couples in which the male partner has undergone vasectomy, allowing assessment of device performance independent of pregnancy risk. Participants will use the device during four separate acts of vaginal intercourse over approximately one month, with data collected via genital examinations, participant diaries, post-use surveys, and pre- and post-coital vaginal swabs analyzed for prostate-specific antigen (PSA) to assess semen leakage. The primary objective is to evaluate safety, with secondary assessment of barrier effectiveness and exploratory evaluation of device performance and user satisfaction compared to traditional condoms.

02

Conditions studied

  • Male Contraception
  • Contraceptive Device
  • Pregnancy Prevention
  • Prevention of Semen Exposure During Intercourse
03

In context

Lead sponsor

Indiana University is the lead sponsor of 990 studies on the registry; 201 are open to participants now.

Of its 150 completed or terminated interventional studies of FDA-regulated products, 118 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:• Heterosexual couples in monogamous stable relationships (>6 months);

  • Both male and female participants are required to have >18 years old prior to entering the study;
  • Eligible men are those with a prior vasectomy and documented azoospermia on semen analysis prior to the baseline visit;
  • Patients must provide a signed and dated form, indicating their understanding and agreement to participate;
  • Patients must be willing to comply with all study procedures and be available for the duration of the study period;
  • Both male and female participants are required to have prior experience using a male condom during intercourse;
  • All participants (both male and female) must be in good general health based on their medical history and physical examination. At study entry, male participants must have no open penile lesions or lacerations as confirmed by genital exam, and female participants must have no vaginal lesions or lacerations as confirmed by vaginal exam. Participants with significant genital findings at baseline will not be included in this study.

Exclusion Criteria:

  • Participants will be excluded if they do not meet any of the inclusion criteria. Exclusion criteria comprise:

    • Couples who are not heterosexual or monogamous;
    • Relationships lasting less than six months;
    • Individuals under 18 years of age;
    • Male participants who have not undergone a prior vasectomy or who do not have a semen analysis confirming azoospermia before the baseline visit;
    • Inability or unwillingness to provide signed and dated informed consent;
    • Inability to comply with all study procedures;
    • Unavailability for the full duration of the study;
    • Either partner lacking prior experience with male condom use during intercourse;
    • Presence of penile or vaginal lesions or lacerations in either partner, detected during medical physical examination;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Galactic cap

    Increase use of male contraception; Preventing transmission of bodily fluids

    Device: Galactic Cap

Interventions

  • DeviceGalactic Cap

    Use galactic cap four times per week for two weeks

06

What researchers measure

Primary outcomes

  1. Device Safety

    Any potential risk or adverse events associated with device use

    Time frame: Day 1 to Day 30

Secondary outcomes

  1. Barrier efficacy

    Rate of prostate specific antigen (PSA) detection in post coital vaginal samples

    Time frame: Day 7 through day 30

07

Study locations

2 of 2 sites recruiting
  • Indiana University Men's Health Clinic Indiana University Health North Hospital
    Carmel, Indiana 46032, United States
    Recruiting
  • Indiana University Men's Health Clinic Indiana University Health North Hospital
    Indianapolis, Indiana 46202, United States
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2026 (actual). Primary completion is estimated for Apr 2027, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Oct 19, 2026
Primary completionEst.
Apr 19, 2027
CompletionEst.
Apr 19, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07947186
Lead sponsor
Indiana University
Responsible party
Helen Levey Bernie (Assistant Professor of Urology, Indiana University) — Principal investigator
First posted
Nov 18, 2026
Start date
Oct 19, 2026
Primary completion
Apr 19, 2027 (estimated)
Completion
Apr 19, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion